Further, it has been demonstrated that S63845 can successfully induce apoptosis when used in combination with either lapatinib, docetaxel, or trastuzumab (HER2-targeting monoclonal antibody) in another HER2-amplified breast cancer cell line, SK-BR-3, through liberation of pro-apoptotic BH3-only activator BIM [117]. Here, ERBB2 is linked to breast cancer.